Pointstate Capital Lp adds Medivation Inc (MDVN) to its portfolio

Medivation Inc (MDVN) : Pointstate Capital Lp added new position in Medivation Inc during the most recent quarter end. The investment management firm now holds 2,067,361 shares of Medivation Inc which is valued at $136,487,173 , the company said in a statement filed on Aug 15, 2016 with the SEC.Medivation Inc makes up approximately 3.49% of Pointstate Capital Lp’s portfolio.

Other Hedge Funds, Including , Janus Capital Management boosted its stake in MDVN in the latest quarter, The investment management firm added 35,986 additional shares and now holds a total of 3,579,877 shares of Medivation Inc which is valued at $236,343,480. Medivation Inc makes up approx 0.19% of Janus Capital Management’s portfolio.I.g. Investment Management Ltd. boosted its stake in MDVN in the latest quarter, The investment management firm added 3,329 additional shares and now holds a total of 98,058 shares of Medivation Inc which is valued at $6,202,169. Medivation Inc makes up approx 0.02% of I.g. Investment Management Ltd.’s portfolio.Gsa Capital Partners Llp boosted its stake in MDVN in the latest quarter, The investment management firm added 5,698 additional shares and now holds a total of 11,385 shares of Medivation Inc which is valued at $720,101. Medivation Inc makes up approx 0.04% of Gsa Capital Partners Llp’s portfolio. Macroview Investment Management added MDVN to its portfolio by purchasing 10 company shares during the most recent quarter which is valued at $641.

Medivation Inc opened for trading at $80.45 and hit $80.98 on the upside on Thursday, eventually ending the session at $80.93, with a gain of 0.46% or 0.37 points. The heightened volatility saw the trading volume jump to 67,00,788 shares. Company has a market cap of $13,429 M.

On the company’s financial health, Medivation Inc reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $0.26. The company had revenue of $206.20 million for the quarter, compared to analysts expectations of $209.92 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 EPS.

Many Wall Street Analysts have commented on Medivation Inc. Medivation Inc was Downgraded by Stifel to ” Hold” on Aug 23, 2016. Medivation Inc was Downgraded by Credit Suisse to ” Neutral” on Aug 23, 2016. Company shares were Downgraded by Maxim Group on Aug 23, 2016 to ” Hold”, Firm has raised the Price Target to $ 81.50 from a previous price target of $76 .

Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *